Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
about
Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsParadoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseCurrent evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisSpondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitisUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitisASAS/EULAR recommendations for the management of ankylosing spondylitis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.Synovial Tissue Response to Treatment with TNF Blockers in Peripheral SpondyloarthritisUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Anti-TNF-alpha agents in the treatment of psoriatic arthritis.Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers.Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Infliximab in the treatment of ankylosing spondylitis.Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection.Cat scratch disease during infliximab therapy: a case report and literature review.The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.Management of ankylosing spondylitis with infliximab.Infliximab-induced intertriginous psoriasis in patient with Crohn's disease.Study of Molecular Mechanisms Involved in the Pathogenesis of Immune-Mediated Inflammatory Diseases, using Psoriasis As a Model.Immunomodulatory drugs for psoriasis.A life-threatening abscess in a patient treated with a tumour necrosis factor-alpha antagonist: a case report.Severe infliximab-induced psoriasis treated with adalimumab switching.Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).Digestive system in psoriasis: an update.Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.Update on psoriatic arthritis.TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies.2014 European Guideline on the management of sexually acquired reactive arthritis.
P2860
Q22305935-B60F26C1-5CD4-4B65-895C-7A68074A59FEQ26738918-E2D34AAB-12A8-49AD-9FC6-D8DDEF227EA0Q26822029-FE78EB52-83D3-4173-B1DE-C1686C609496Q33222422-1E0BECD2-BB92-4150-9987-34D76A5B15DFQ33624763-9536CA2F-468B-4AEB-8004-6B17B312BB05Q35170882-42B7059A-8F75-4C2D-BE52-2692001AF176Q35579352-C4FDC998-E4F6-4462-905B-532609FD8B53Q35636708-AB7CF888-E570-4A4B-A835-7B6C1626E9C6Q35637012-252BB506-39F3-4105-9FB2-34EB87F52661Q35638252-2E589E2B-B871-4D95-A64C-84AED91EFF4BQ35638537-97227F59-0F46-42DE-A34F-5B5B1CA71FCBQ35687019-7C968015-4E1A-4A7B-AC0A-BFE223766625Q36171750-BBEF1E17-3C2C-48C7-AF54-A4E4DDFDA62CQ36377196-4C03013E-44C5-4C74-83F9-AC1B6108575DQ36687029-0D870859-E3F3-4E31-88B4-EC50AC0A2526Q36708366-02FCE30A-26A7-4E9A-AA10-8E015D2DA89BQ37189376-6CB1390F-349B-4953-8B01-2FE53215C941Q37290474-038F261C-2CF4-49EC-ABC0-340932BEA8FAQ37299387-0F2AD42C-4B1D-45A3-994F-73F561890AD5Q37729028-251CCDBD-8DE5-4E60-9A49-C24598D87F9FQ37854163-29708726-AA1C-4599-A348-C989ACD38FFCQ38228997-4D550B15-263D-4C9C-A599-C9156EE98EF5Q38303209-6134C762-F08D-4B5D-8931-C9481D9ECAFBQ38674463-B5714D78-A130-4752-8846-A231A59135D1Q38993236-DE1FFEE2-88A2-45E0-A457-42C9CC36B1EBQ41848965-4E1CC3DE-E3A7-4F9D-AF48-0F23FE919AE5Q42003306-C7362D72-EE71-4AD0-857A-C5119951A823Q42943454-6F4EC159-B436-4AE2-A332-783520F4B787Q43282843-B7145788-9ED1-480C-8126-1B55CAA1CD08Q44576832-CCF51F39-8C4C-4A0F-BAB1-2F2090E7CCDAQ45075976-5C4831DB-D1B6-479E-A6E3-7B0028644CE8Q46466020-7848B53C-1522-4561-A553-6D7D6D56459CQ46970183-83E9C141-1C81-4919-98CB-3825E1913BC5Q47256882-545D16C3-8875-436B-9875-C1BD810EDA49Q48319094-C23A9B3E-69B4-4748-925F-980E3377EC15Q51052396-520A3E2A-AB9F-4856-A3F0-2E0FAC2E9593Q53272760-3800DD2D-F812-474E-A018-598D7D1A5186
P2860
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Systematic safety follow up in ...... e pathogenesis of the disease?
@ast
Systematic safety follow up in ...... e pathogenesis of the disease?
@en
type
label
Systematic safety follow up in ...... e pathogenesis of the disease?
@ast
Systematic safety follow up in ...... e pathogenesis of the disease?
@en
prefLabel
Systematic safety follow up in ...... e pathogenesis of the disease?
@ast
Systematic safety follow up in ...... e pathogenesis of the disease?
@en
P2093
P2860
P356
P1476
Systematic safety follow up in ...... e pathogenesis of the disease?
@en
P2093
De Keyser F
Herssens A
Kruithof E
Mielants H
Van den Bosch F
Van den Bossche N
P2860
P304
P356
10.1136/ARD.62.9.829
P407
P577
2003-09-01T00:00:00Z